Neurocrine Biosciences Inc (NBIX)
139.36
-1.19
(-0.85%)
USD |
NASDAQ |
May 22, 16:00
139.36
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Free Cash Flow: 614.40M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | 614.40M |
| December 31, 2023 | 361.60M |
| September 30, 2023 | 384.70M |
| June 30, 2023 | 280.80M |
| March 31, 2023 | 237.30M |
| December 31, 2022 | 322.90M |
| September 30, 2022 | 177.00M |
| June 30, 2022 | 132.60M |
| March 31, 2022 | 102.20M |
| December 31, 2021 | 233.10M |
| September 30, 2021 | 327.80M |
| June 30, 2021 | 250.90M |
| March 31, 2021 | 266.20M |
| December 31, 2020 | 217.60M |
| September 30, 2020 | 222.30M |
| June 30, 2020 | 337.40M |
| March 31, 2020 | 282.90M |
| December 31, 2019 | 132.30M |
| September 30, 2019 | 82.09M |
| June 30, 2019 | 44.35M |
| March 31, 2019 | 0.486M |
| December 31, 2018 | 76.60M |
| September 30, 2018 | 70.31M |
| June 30, 2018 | 1.634M |
| March 31, 2018 | -62.84M |
| Date | Value |
|---|---|
| December 31, 2017 | -101.27M |
| September 30, 2017 | -171.44M |
| June 30, 2017 | -191.11M |
| March 31, 2017 | -159.06M |
| December 31, 2016 | -110.29M |
| September 30, 2016 | -94.35M |
| June 30, 2016 | -81.45M |
| March 31, 2016 | -51.42M |
| December 31, 2015 | -39.93M |
| September 30, 2015 | -39.65M |
| June 30, 2015 | -33.13M |
| March 31, 2015 | -57.19M |
| December 31, 2014 | -48.75M |
| September 30, 2014 | -44.07M |
| June 30, 2014 | -42.52M |
| March 31, 2014 | -42.03M |
| December 31, 2013 | -30.15M |
| September 30, 2013 | -28.03M |
| June 30, 2013 | -25.83M |
| March 31, 2013 | -22.80M |
| December 31, 2012 | -36.26M |
| September 30, 2012 | -16.33M |
| June 30, 2012 | -5.514M |
| March 31, 2012 | -4.456M |
| December 31, 2011 | -1.448M |
Free Cash Flow Range, Past 5 Years
44.35M
Minimum
Jun 2019
614.40M
Maximum
Mar 2024
250.52M
Average
244.10M
Median
Free Cash Flow Benchmarks
| Globus Medical Inc | 151.72M |
| Inspire Medical Systems Inc | 3.285M |
| AIM ImmunoTech Inc | -23.04M |
| Protalix BioTherapeutics Inc | 4.369M |
| Armata Pharmaceuticals Inc | -46.82M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 130.30M |
| Cash from Investing (Quarterly) | -55.00M |
| Cash from Financing (Quarterly) | 69.90M |
| Free Cash Flow Per Share (Quarterly) | 1.150 |
| Free Cash Flow to Equity (Quarterly) | 30.20M |
| Free Cash Flow to Firm (Quarterly) | 120.48M |
| Free Cash Flow Yield | 4.33% |